News

Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency. 

 If you would like to receive a notification via e-mail when we publish a news update please submit your e-mail adress below. 

I have read and accepted the Impilo privacy policy

Jul 1 2021

Mallax acquires Sana Pharma Medical and creates a new Nordic pharmaceutical platform

Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic pharmaceutical platform.

23 Jun 2021

Impilo’s divestment of NutraQ to Orkla completed

On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company was established in Norway in 2002 and at Impilo’s entry in 2017, the company had a strong presence in Norway, Sweden, Finland, Czech Republic and an emerging presence in Denmark.

22 Mar 2021

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a novel, recombinant human arginase 1 enzyme that has been shown to lower toxic levels of the amino acid arginine in patients with Arginase 1 Deficiency (ARG1-D). People living with ARG1-D, a rare, progressive disease characterized by high levels of arginine, may experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability and early mortality.

20 Jan 2021

Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research Organization

Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been acquired by the leading Nordic healthcare investment company, Impilo, together with the management team of Scantox. The Company is formerly known as Charles River Copenhagen A/S and will today be renamed to Scantox A/S and continue its business operations as a fully independent company.

4 Jan 2021

Immedica and WinHealth enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries

Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area , South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. The pharmaceutical drug product Ravicti® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercialize the product in UCD in the countries of the specified territory.

15 Dec 2020

Impilo and Anders Larnholt form a partnership to create a new pan‐European pharmaceutical platform

Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax Pharmaceuticals AB (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with established pharmaceuticals and OTC products for customers and patients across Europe.

6 Nov 2020

Immedica acquires the rights for Ravicti® and Buphenyl® for Japan from Horizon Therapeutics plc.

Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol phenylbutyrate) indicated for the treatment of Urea Cycle Disorders (UCD), in Japan from Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon).

29 Apr 2020

PharmaMar signs an agreement with Immedica

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and some Middle Eastern countries

19 Nov 2019

The Swedish Financial Supervisory Authority has approved the consortium of investors arranged by Impilo as new owners of Euro Accident Livförsäkring

01 Oct 2019

Immedica acquires the rights for Ophthalmology products for European countries

Immedica Pharma AB (Immedica) has acquired rights to four ophthalmology products involving indications for the treatment of glaucoma, allergic conjunctivitis, and inflammatory conditions of the eye, in certain European countries from Novartis. The deal encompasses commercial and distribution rights and intellectual property for the four products in the territories.

Se flere nyheder

Media

We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Go to Cision

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.